VIP
Neuropeptide
28-amino-acid neuropeptide acting through VPAC receptors, studied in smooth-muscle, vascular and immune-cell signalling research.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- Neuropeptide
- Category
- Immune & Inflammation
- Type
- Single compound
- Development and regulatory status
- Synthetic form aviptadil approved in some countries; not FDA-approved
What researchers study
VIP is a 28-amino-acid neuropeptide found across the nervous system, gut and immune cells. It signals through VPAC receptors to relax smooth muscle, dilate blood vessels and modulate immune-cell activity.
Research areas
- Vasodilation and smooth-muscle relaxation assays
- Gut motility and mucosal secretion studies
- Immune-cell regulation and cytokine models
- Pulmonary vasodilation and lung-injury models
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- review
A 2025 meta-analysis of nine aviptadil studies in acute respiratory distress syndrome (665 patients) found survival benefit remained uncertain
- supplier datasheet
Supplier literature lists VIP actions including vessel dilation, airway opening, smooth-muscle relaxation and effects on many immune cell types
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- KPVAlpha-MSH fragment with anti-inflammatory activity, studied alongside VIP in gut-inflammation models
- Larazotide (AT-1001)Barrier-protective peptide studied in intestinal permeability models
- Thymosin Alpha-1Immune-modulating peptide compared with VIP in immune-regulation studies
